Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). - Wikidata - awgldk - TriplyDB

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

http://www.wikidata.org/entity/Q47570250

about

New β-Lactamase Inhibitors in the Clinic New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Ceftaroline fosamil: a brief clinical review.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam New antibiotic agents in the pipeline and how they can help overcome microbial resistance.In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study New β-lactam-β-lactamase inhibitor combinations in clinical development.Combating multidrug-resistant Gram-negative bacterial infections.Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.AmpC β-lactamase induction by avibactam and relebactam.

P2860

Q26747150-D294B32A-4F55-4F3E-9FC5-E994B9780C59 Q33622976-68513FA4-3328-44F2-BE54-99DA6A9DE9D6 Q33939080-92F08467-D9BC-430C-B06C-D52836D17443 Q34058217-07D570B5-DC46-46C6-9B31-043C3E76871E Q34325573-F1DB7BC1-7E02-4E97-9A42-0F174D5A8F21 Q34375204-14FFC078-44F9-458A-A57A-E0CF03B2D609 Q34402134-630A12CB-BC53-4B12-9BEA-6AA061337669 Q35960745-6BD19C32-56B2-4B48-8D2D-F4509D8C440A Q36075893-84392769-DE10-4314-AFD7-CB2F0DF61A59 Q36644679-D61E4AC9-6E84-4C45-AD94-EC4D4E80B991 Q36845895-AB6AC34E-EA84-4FB1-B9CB-C52D1B8347DA Q37263425-4C4C5F88-2498-45E9-924B-F343CE1FF1E9 Q38076455-98C436D6-8B91-4A08-B13C-6DBDB1C8D88C Q38161570-DA635079-F08A-4B17-A288-A4FF41FEDF95 Q39001350-D603633A-89FA-4844-8DA7-84E11D0D4A91 Q40163436-688D0B2A-37C0-4673-AC83-EBA7732C3029 Q40284963-5C182EB0-564C-43CE-993C-746E092AE264 Q40967518-37F56E0B-C918-4160-8BFD-5C484F1B1358 Q41098656-AF5B83E7-6D8B-4AAE-B33C-88494C67C17E Q41508049-42B8C394-9209-4C0E-8610-C70A74E96FBB Q41992904-96A61E07-E243-4653-9AE8-7CDF9F672363

P2860

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

http://www.wikidata.org/entity/Q47570250

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Characterization of β-lactamas ...... taroline + avibactam (NXL104).

@en

Characterization of β-lactamas ...... d with ceftaroline + avibactam

@nl

type

label

Characterization of β-lactamas ...... taroline + avibactam (NXL104).

@en

Characterization of β-lactamas ...... d with ceftaroline + avibactam

@nl

prefLabel

Characterization of β-lactamas ...... taroline + avibactam (NXL104).

@en

Characterization of β-lactamas ...... d with ceftaroline + avibactam

@nl

P1433

Q47570250-0B5B09C0-0CAA-417E-AEF0-1547D51A67D8

P1476

Q47570250-AF216198-ADF6-46A3-9780-A46D13D04382

P2093

Q47570250-42259C87-0BAB-4A86-BABA-A7FA05C95447

Q47570250-59177C24-E8F2-4104-86B2-7003E9B709D3

Q47570250-5F3CA38A-6102-4CA8-B30E-1F389CA29456

Q47570250-AB23CA04-C610-41C0-8F60-D57E24D8DBCD

Q47570250-EB11BD92-86D5-4F26-8D0F-6851EB8A0850

P2860

Q47570250-2DDB5CF7-26B3-4C1B-910E-94E44199C397

Q47570250-4D1656B8-60D0-48CB-AA01-8A092D454C1D

Q47570250-5DE8DE0F-E9B7-4DFA-97CE-528341EB9F4E

Q47570250-63B45E2D-501F-4DA0-877B-A806B36718BA

Q47570250-8E8D1B60-0F6B-4EC0-9BA4-5E8A7DA77BD2

Q47570250-B56AC462-937A-4613-9DCD-CF65A53524AF

Q47570250-BE9C387A-4764-4DB9-B97F-A3E8FC3C6909

Q47570250-C5ABBB6B-DD00-4EB0-9679-FAD57D82EC33

Q47570250-C66CB248-C54A-445F-9F77-04180942A8AB

P304

Q47570250-8EFDF56C-9F7F-4D51-A874-CEFC1DBDC32C

P31

Q47570250-B3CE7992-034F-40AC-AD58-5530D595A35D

P356

Q47570250-FE27DCF5-7499-4167-97E9-94C6F8E199E6

P407

Q47570250-6B0F0030-6C82-4557-8B81-99988EC82AC9

P433

Q47570250-313DA4D2-19C2-4BC2-92DF-489838EA00F0

P478

Q47570250-6CEE6A7F-C7E4-400C-BB7C-38FEFE4D9A80

P50

Q47570250-AE4C9C6A-E75C-4FFF-8D47-8EE4A991A597

P577

Q47570250-012D59C2-B4ED-4B3F-8DC4-3D899D8EC47B

P5875

Q47570250-ECF9292F-ED33-4B3B-862C-4B0D13058198

P698

Q47570250-02CEEBC7-DAC2-4515-B9C6-7F230EC3B72A

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Characterization of β-lactamas ...... taroline + avibactam (NXL104).

@en

P2093

David M Livermore

http://www.w3.org/2001/XMLSchema#string

Kevin Barker

http://www.w3.org/2001/XMLSchema#string

Marina Warner

http://www.w3.org/2001/XMLSchema#string

Russell Hope

http://www.w3.org/2001/XMLSchema#string

Shazad Mushtaq

http://www.w3.org/2001/XMLSchema#string

P2860

Role of the omega-loop in the activity, substrate specificity, and structure of class A beta-lactamase

Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

IRT and CMT beta-lactamases and inhibitor resistance.

Crystallization and preliminary X-ray crystallographic analyses of CMY-1 and CMY-10, plasmidic class C beta-lactamases with extended substrate spectrum.

Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC beta-lactamase of a Serratia marcescens clinical isolate.

Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.

The D-methyl group in beta-lactamase evolution: evidence from the Y221G and GC1 mutants of the class C beta-lactamase of Enterobacter cloacae P99.

Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases.

Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases.

P304

1354-1358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKS079

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221970390

http://www.w3.org/2001/XMLSchema#string

P698

22441578

http://www.w3.org/2001/XMLSchema#string